Cancer Jab Shows 'Unprecedented' Results
A new triple-action cancer jab, amivantamab, has shown "unprecedented" trial results by completely eradicating tumors in some patients with advanced, treatment-resistant cancers. This innovative injection, which blocks cancer-promoting proteins and activates the immune system, offers significant hope after 15 out of 102 patients experienced full tumor eradication, despite previous treatments failing.